- China
- United States
- Singapore
- Japan
- South Korea
- India
- Australia
- Seed
- Series A
- Series B
- Series C
- Growth
- Biopharmaceuticals
- Therapeutics
- Medical Devices
- Diagnostics
- Life Sciences
- Healthcare
About
Lilly Asia Ventures is a Shanghai-based biomedical venture capital firm originated in 2008 as a corporate venture subsidiary of Eli Lilly, spun off as an independent investment management company in 2011. With approximately $4.5 billion in AUM and offices in Shanghai, Hong Kong, and Palo Alto, LAV invests in biopharmaceuticals, medical technologies, and diagnostics from seed through publicly traded stages across Asia and the United States.
Lilly Asia Ventures focuses on becoming the trusted partner for exceptional entrepreneurs seeking smart capital to build great companies developing breakthrough products that treat diseases and improve human health. The thesis leverages deep biomedical resources and global connections.
Lilly Asia Ventures is led by Founder and Managing Partner Yi Shi, with a team of over 50 distinguished professionals across science, medicine, investment, and operations. The firm originated in 2008 as a corporate venture subsidiary of Eli Lilly and spun off as an independent investment management company in 2011. The partners bring deep expertise in preclinical and clinical development, regulatory know-how, and market insights, supported by a large network of scientific advisors and a portfolio that includes 1 unicorn and IPOs such as Alector, ArriVent, and Insilico.
Lilly Asia Ventures Contacts Information